TP53 and cancer: Survival was evaluated by Kaplan-Meier methods and Cox regression.<h4>Results</h4><i>TP53</i> and <i>PTEN</i> mutations were identified in 68% and 47% of cancer samples, respectively, versus <5% among controls.